Gamida Cell
Gamida Cell FY 2021: net loss $89.8M
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001213900-22-014643
- Document
- 10-K
- Exhibit 4.3
- Description of securities
- Exhibit 10.1
- Form of indemnification agreement
- Exhibit 10.6
- 2017 share incentive plan, as amended
Key figures from this report
These are the numbers Gamida Cell reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Net income−$89.8MAgainst −$61.6M in FY 202010-K income statement, on EDGAR
- Cash and cash equivalents$55.9M−56% from $127.2M in FY 2020Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$81.8MAgainst −$50.2M in FY 202010-K cash flow statement, on EDGAR
Similar companies
Same SIC code (2836) and public float not reported.
- Adaptimmune Therapeutics ADAP
- Adverum Biotechnologies ADVM
- AgomAb Therapeutics AGMB
- Alvotech ALVO
- Argenx ARGX
